Drug Transporter (DT) Information

General Information of DT
DT ID DTD0008
Gene Name SLCO1B1
Protein Name Organic anion transporting polypeptide 1B1
Gene ID
10599
UniProt ID
Q9Y6L6
TCDB ID
2.A.60.1.5
3D Structure

Modelled DT Structure

Method: multi-sequence alignment based machine learning

Detail: Structure Info

Synonyms LST-1; LST1; Liver-specific organic anion transporter 1; OATP-2; OATP-C; OATP1B1; OATP2; OATPC; SLC21A6; SLCO1B1; Sodium-independent organic anion-transporting polypeptide 2; Solute carrier family 21 member 6; Solute carrier organic anion transporter family member 1B1
DT Family Organo Anion Transporter (OAT) Family ;
Tissue Specificity High expressed in sinusoidal (basolateral) membrane of hepatocytes, and is expressed uniformly throughout the lobules
Function This transporter involved in the clearance of bile acids and organic anions from the liver. Mediates the Na(+)-independent uptake of organic anions such as pravastatin, taurocholate, methotrexate, dehydroepiandrosterone sulfate, 17-beta-glucuronosyl estradiol, estrone sulfate, prostaglandin E2, thromboxane B2, leukotriene C3, leukotriene E4, thyroxine and triiodothyronine.
Disease(s) Breast cancer [ICD-11: 2C60-2C6Z]
Chronic hepatitis C infection [ICD-11: 1E51.1]
Diabetes [ICD-11: 5A10-5A14]
Diarrhea-predominant irritable bowel syndrome [ICD-11: DD91.01]
Dyslipidaemias [ICD-11: 5C8Z]
Edema associated with congestive heart failure [ICD-11: BD10]
Leukemia [ICD-11: 2A60-2B33]
Metastatic colorectal cancer [ICD-11: 2B91]
Pemphigus vulgaris [ICD-11: EB40.0]
Endogenous Substrate(s) Bisglucuronosyl bilirubin; Cholate; Dehydroepiandrosterone sulfate; Eicosanoids; Monoglucuronosyl bilirubin; Thyroid hormones; Tauroursodeoxycholate
Variability Data of This Drug Transporter (DT)

Regulatory Variability Data of This DT (VARIDT 3.0)

(α) Microbiota Influence of This DT
Microbiota Influence (MBI)

(β) Post-translational Modification of This DT
Post-translational Modification (PTM)

(γ) Transcriptional Regulation of This DT
Transcriptional Regulation (TSR)

(δ) Epigenetic Regulation of This DT
Epigenetic Regulation (EGR)

(ε) Exogenous Modulation of This DT
Exogenous Modulation (EGM)

General Variability Data of This DT (VARIDT 1.0)

(α) Genetic Polymorphisms of This DT
Genetic Polymorphisms of This DT (GPD)

(β) Disease-specific Protein Abundances of This DT
Disease-specific Protein Abundances of This DT (DPAD)

(γ) Species- and Tissue-specific DT Abundances
Species/Tissue-specific Protein Abundances of This DT (S/TPAD)
Molecular Transporting Profile of This DT

Full List of Drug(s) Transported by This DT

 Approved Drug

 Click to Show/Hide the Full List of Drug:          63 Drugs in Total
Drug Name Highest Status Detail Indication ICD 11 Ref
Atorvastatin
 Approved Drug Info Hyperlipidaemia 5C8Z [1]
Axitinib
 Approved Drug Info Advanced renal cell carcinoma 2C90 [2]
Bosentan
 Approved Drug Info Pulmonary arterial hypertension BB01.0 [3]
Bromfenac
 Approved Drug Info Ocular inflammation 9C61.24 [4]
Caspofungin
 Approved Drug Info Fungal infections 1F20-1F2Z [5]
Cefazolin
 Approved Drug Info Methicillin-susceptible staphylococcus aureus 1B74.0 [5]
Cefditoren
 Approved Drug Info Acute bacterial exacerbation of chronic bronchitis CA20.1 [5]
Cefoperazone
 Approved Drug Info Pseudomonas bacterial infections 1B92 [5]
Cerivastatin
 Approved Drug Info Hyperlipidaemia 5C8Z [6]
Chenodeoxycholic acid
 Approved Drug Info Primary biliary cirrhosis DB96.1 [7]
Cholic acid
 Approved Drug Info Synthesis disorders 5C52.10 [5]
Cilostazol
 Approved Drug Info Intermittent claudication BD40.00 [8]
Crizotinib
 Approved Drug Info Non-small cell lung cancer 2C25 [9]
Darunavir
 Approved Drug Info Human immunodeficiency virus infection 1C62.Z [5]
Dasatinib
 Approved Drug Info Multiple myeloma 2A83 [9]
Dehydroepiandrosterone sulfate
 Approved Drug Info Dyspareunia GA12 [5]
Dinoprostone
 Approved Drug Info Medical abortion JA00.1 [5]
Docetaxel
 Approved Drug Info Lung cancer 2C25 [6]
Eluxadoline
 Approved Drug Info Diarrhea-predominant irritable bowel syndrome DD91.01 [10]
Enalapril
 Approved Drug Info High blood pressure BA00 [11]
Entacapone
 Approved Drug Info Parkinson's Disease 8A00.0 [4]
Estrone sulfate
 Approved Drug Info Menopausal symptoms MF32 [12]
Etoposide
 Approved Drug Info Testicular cancer 2C80 [13]
Ezetimibe
 Approved Drug Info Hypercholesterolemia 5C80.0 [14]
Fluorescein
 Approved Drug Info Ocular disease 9E1Z [4]
Fluvastatin
 Approved Drug Info Hypercholesterolemia 5C80.0 [15]
Gadobenate dimeglumine
 Approved Drug Info CNS imaging XD47Y1 [16]
Gefitinib
 Approved Drug Info Urethral cancer 2F78 [9]
Hydroxyurea
 Approved Drug Info Chronic myelogenous leukemia 2A20.0 [17]
Imatinib
 Approved Drug Info Gastrointestinal stromal tumor 2B5B [9]
Levothyroxine
 Approved Drug Info Hypothyroidism 5A00.2 [18]
Liothyronine
 Approved Drug Info Hypothyroidism 5A00.2 [18]
Lopinavir
 Approved Drug Info Human immunodeficiency virus infection 1C62.Z [5]
Lovastatin
 Approved Drug Info Hypercholesterolemia 5C80.0 [19]
Mesalazine
 Approved Drug Info Recurrent ventricular fibrillation BC71.1 [20]
Methotrexate
 Approved Drug Info Leukemia 2A60-2B33 [21]
Mycophenolate mofetil
 Approved Drug Info Pemphigus vulgaris EB40.0 [22]
Nafcillin
 Approved Drug Info Bacterial infections 1A00-1H0Z [5]
Nateglinide
 Approved Drug Info Diabetes 5A10-5A14 [4]
Nilotinib
 Approved Drug Info Chronic myelogenous leukemia 2A20.0 [9]
Olmesartan medoxomil
 Approved Drug Info High blood pressure BA00 [23]
Ouabain
 Approved Drug Info Heart failure BD1Z [24]
Paclitaxel
 Approved Drug Info Breast cancer 2C60-2C6Z [25]
Pazopanib hydrochloride
 Approved Drug Info Renal cell carcinoma 2C90 [5]
Pitavastatin
 Approved Drug Info Primary hyperlipidemia and mixed dyslipidemia 5C8Z [26]
Pitavastatin calcium
 Approved Drug Info Dyslipidaemias 5C8Z [27]
Pravastatin
 Approved Drug Info Hypercholesterolemia 5C80.0 [27]
Regorafenib
 Approved Drug Info Metastatic colorectal cancer 2B91 [28]
Repaglinide
 Approved Drug Info Type 2 diabetes 5A11 [29]
Rifampicin
 Approved Drug Info Tuberculosis 1B1Z [30]
Rosuvastatin
 Approved Drug Info Hypercholesterolemia 5C80.0 [31]
Saquinavir
 Approved Drug Info Human immunodeficiency virus infection 1C62.Z [5]
Simeprevir
 Approved Drug Info Chronic hepatitis C infection 1E51.1 [32]
Simvastatin
 Approved Drug Info Hypercholesterolemia 5C80.0 [33]
Sirolimus
 Approved Drug Info Organ transplant rejection NE84 [34]
Sorafenib
 Approved Drug Info Pancreatic cancer 2C10 [9]
Sunitinib
 Approved Drug Info Imatinib-resistant gastrointestinal stromal tumor 2B5B [9]
Technetium (99MTC) mebrofenin
 Approved Drug Info Imaging of liver and gallbladder XD47Y1 [29]
Temocapril
 Approved Drug Info High blood pressure BA00 [5]
Torsemide
 Approved Drug Info Edema associated with congestive heart failure BD10 [35]
Valsartan
 Approved Drug Info High blood pressure BA00 [24]
Vandetanib
 Approved Drug Info Thyroid gland tumours 2D10 [9]
Vemurafenib
 Approved Drug Info Thyroid cancer 2D10 [9]

 Clinical Trial Drug

 Click to Show/Hide the Full List of Drug:          12 Drugs in Total
Drug Name Highest Status Detail Indication ICD 11 Ref
Benzylpenicillin
 Phase 4 Drug Info Gram-positive bacteria infections 1A00-1H0Z [5]
Primovist
 Phase 4 Drug Info Lung cancer 2C25 [5]
Atrasentan
 Phase 3 Drug Info Endothelial dysfunction BE2Z [5]
Glycocholic acid
 Phase 3 Drug Info Bile acid synthesis defect 5C52.11 [5]
Karenitecin
 Phase 3 Drug Info Ovarian cancer 2C73 [5]
BQ-123
 Phase 2 Drug Info ST-Elevation myocardial infarction BA41.0 [5]
Cholyl lysyl fluorescein
 Phase 2 Drug Info Hepatitis virus infection 1E5Z [5]
Danoprevir
 Phase 2 Drug Info Hepatitis C virus infection 1E50.2, 1E51.1 [6]
Flavopiridol
 Phase 2 Drug Info Chronic lymphocytic leukemia 2A82.0 [5]
SN-38
 Phase 2 Drug Info Colon cancer 2B90.Z [5]
YM758
 Phase 2 Drug Info Angina pectoris BA40 [5]
Gimatecan
 Phase 1/2 Drug Info Brain and central nervous system tumors 2A00 [5]

 Withdrawn, Discontinued or Preclinical Drug

 Click to Show/Hide the Full List of Drug:            6 Drugs in Total
Drug Name Highest Status Detail Indication ICD 11 Ref
TR-14035
 Discontinued in Phase 1 Drug Info Multiple scierosis 8A40 [36]
Leukotriene E4
 Preclinical Drug Info Asthma CA23 [5]
Sodium taurocholate
 Preclinical Drug Info Type 2 diabetes 5A11 [24]
[D-Ala2, D-Leu5]-enkephalin
 Preclinical Drug Info Pain MG30-MG7Z [5]
Sincalide
 Preclinical Drug Info Discovery agent N.A. [5]
Taurocholic acid
 Terminated Drug Info Type 2 diabetes 5A11 [18]

Endogenous Metabolites (EMs) Handled by This DT

 Endogenous Metabolites (EMs)

 Click to Show/Hide the Full List of EMs:            4 EMs in Total
EM Name PubChem CID Detail Experimental Material Ref
Bile salt unspecific N.A. EM Info Unclear experiment used for identifying this EM [37]
Hormone metabolite unspecific N.A. EM Info Unclear experiment used for identifying this EM [37]
Thyroxine
5819
EM Info Unclear experiment used for identifying this EM [37]
Triiodothyronine
5920
EM Info Unclear experiment used for identifying this EM [37]

Drug-DT Affinity Assessed by Cell Line

 Approved Drug

 Click to Show/Hide the Full List of Drug:          36 Drugs in Total
Drug Name Highest Status Detail Cell Line Affinity Ref
Atorvastatin Approved Drug Info Human embryonic kidney cells (HEK293)-OATP1B1 Km = 0.77 microM [38]
Atorvastatin Approved Drug Info Human embryonic kidney cells (HEK293)-OATP1B1 Km = 12.4 microM [39]
Atorvastatin Approved Drug Info Human embryonic kidney cells (HEK293)-OATP1B1 Km = 18.9 microM [40]
Bosentan Approved Drug Info Chinese hamster ovary (CHO) cells-OATP1B1 Km = 44 microM [3]
Cilostazol Approved Drug Info Human embryonic kidney cells (HEK293)-OATP1B1 Km = 17.7 microM [8]
Estrone sulfate Approved Drug Info Chinese hamster ovary (CHO) cells-OATP1B1 Km = 0.23 microM [41]
Estrone sulfate Approved Drug Info Chinese hamster ovary (CHO) cells-OATP1B1 Km = 2.4 microM [42]
Estrone sulfate Approved Drug Info Human embryonic kidney cells (HEK293)-OATP1B1 Km = 12.5 microM [43]
Estrone sulfate Approved Drug Info Human embryonic kidney cells (HEK293)-OATP1B1 Km = 0.46 microM [44]
Estrone sulfate Approved Drug Info Human embryonic kidney cells (HEK293)-OATP1B1 Km = 0.0675 microM [45]
Estrone sulfate Approved Drug Info Human embryonic kidney cells (HEK293)-OATP1B1 Km = 7 microM [45]
Estrone sulfate Approved Drug Info Oocytes-OATP1B1 Km = 0.094 microM [45]
Estrone sulfate Approved Drug Info Oocytes-OATP1B1 Km = 5.34 microM [45]
Fluvastatin Approved Drug Info Chinese hamster ovary (CHO) cells-OATP1B1 Km = 1.4 microM [41]
Fluvastatin Approved Drug Info Chinese hamster ovary (CHO) cells-OATP1B1 Km = 3.5 microM [41]
Fluvastatin Approved Drug Info Oocytes-OATP1B1 Km = 31.1 microM [27]
Levothyroxine Approved Drug Info Oocytes-OATP1B1 Km = 3 microM [18]
Liothyronine Approved Drug Info Oocytes-OATP1B1 Km = 2.7 microM [18]
Mesalazine Approved Drug Info Human embryonic kidney cells (HEK293)-OATP1B1 Km = 55.1 microM [20]
Olmesartan medoxomil Approved Drug Info Human embryonic kidney cells (HEK293)-OATP1B1 Km = 12.8 microM [46]
Olmesartan medoxomil Approved Drug Info Oocytes-OATP1B1 Km = 42.6 microM [23]
Pitavastatin calcium Approved Drug Info Human embryonic kidney cells (HEK293)-OATP1B1 Km = 3 microM [44]
Pitavastatin calcium Approved Drug Info Human embryonic kidney cells (HEK293)-OATP1B1 Km = 4.8 microM [47]
Pitavastatin calcium Approved Drug Info Oocytes-OATP1B1 Km = 3.6 microM [48]
Pitavastatin calcium Approved Drug Info Oocytes-OATP1B1 Km = 6.7 microM [27]
Pravastatin Approved Drug Info Human embryonic kidney cells (HEK293)-OATP1B1 Km = 33.7 microM [19]
Pravastatin Approved Drug Info Human embryonic kidney cells (HEK293)-OATP1B1 Km = 85.7 microM [39]
Pravastatin Approved Drug Info Oocytes-OATP1B1 Km = 57.5 microM [27]
Rifampicin Approved Drug Info Human cervical cancer cell line (Hela)-OATP1B1 Km = 1.5 microM [30]
Rifampicin Approved Drug Info Oocytes-OATP1B1 Km = 13 microM [49]
Rosuvastatin Approved Drug Info Human cervical cancer cell line (Hela)-OATP1B1 Km = 4 microM [50]
Rosuvastatin Approved Drug Info Human cervical cancer cell line (Hela)-OATP1B1 Km = 7.3 microM [50]
Rosuvastatin Approved Drug Info Human embryonic kidney cells (HEK293)-OATP1B1 Km = 0.8 microM [31]
Rosuvastatin Approved Drug Info Oocytes-OATP1B1 Km = 8.5 microM [51]
Valsartan Approved Drug Info Chinese hamster ovary (CHO) cells-OATP1B1 Km = 17.8 microM [52]
Valsartan Approved Drug Info Human embryonic kidney cells (HEK293)-OATP1B1 Km = 1.39 microM [53]

 Withdrawn, Discontinued or Preclinical Drug

 Click to Show/Hide the Full List of Drug:          12 Drugs in Total
Drug Name Highest Status Detail Cell Line Affinity Ref
Taurocholic acid Terminated Drug Info Human embryonic kidney cells (HEK293)-OATP1B1 Km = 33.8 microM [19]
Taurocholic acid Terminated Drug Info Oocytes-OATP1B1 Km = 13.6 microM [18]
Bilirubin Investigative Drug Info Human embryonic kidney cells (HEK293)-OATP1B1 Km = 0.1 microM [43]
Bilirubin Investigative Drug Info Human embryonic kidney cells (HEK293)-OATP1B1 Km = 0.28 microM [43]
Bilirubin Investigative Drug Info Oocytes-OATP1B1 Km = 0.0076 microM [54]
Bromsulphthalein Investigative Drug Info Human embryonic kidney cells (HEK293)-OATP1B1 Km = 0.14 microM [43]
Bromsulphthalein Investigative Drug Info Oocytes-OATP1B1 Km = 0.3 microM [55]
Estradiol-17beta-glucuronide Investigative Drug Info Chinese hamster ovary (CHO) cells-OATP1B1 Km = 5.4 microM [42]
Estradiol-17beta-glucuronide Investigative Drug Info Chinese hamster ovary (CHO) cells-OATP1B1 Km = 5.9 microM [56]
Estradiol-17beta-glucuronide Investigative Drug Info Human embryonic kidney cells (HEK293)-OATP1B1 Km = 2.5 microM [57]
Estradiol-17beta-glucuronide Investigative Drug Info Human embryonic kidney cells (HEK293)-OATP1B1 Km = 8.29 microM [44]
Fluo-3 Investigative Drug Info Chinese hamster ovary (CHO) cells-OATP1B1 Km = 2.3 microM [42]
References
1 Rifampicin alters atorvastatin plasma concentration on the basis of SLCO1B1 521T>C polymorphism. Clin Chim Acta. 2009 Jul;405(1-2):49-52.
2 Meta-analysis of contribution of genetic polymorphisms in drug-metabolizing enzymes or transporters to axitinib pharmacokinetics. Eur J Clin Pharmacol. 2012 May;68(5):645-55.
3 Bosentan is a substrate of human OATP1B1 and OATP1B3: inhibition of hepatic uptake as the common mechanism of its interactions with cyclosporin A, rifampicin, and sildenafil. Drug Metab Dispos. 2007 Aug;35(8):1400-7.
4 Organic Anion Transporter 2-Mediated Hepatic Uptake Contributes to the Clearance of High-Permeability-Low-Molecular-Weight Acid and Zwitterion Drugs: Evaluation Using 25 Drugs. J Pharmacol Exp Ther. 2018 Nov;367(2):322-334.
5 Organic anion transporting polypeptide 1B1: a genetically polymorphic transporter of major importance for hepatic drug uptake. Pharmacol Rev. 2011 Mar;63(1):157-81.
6 FDA Drug Development and Drug Interactions
7 Transport of fluorescent chenodeoxycholic acid via the human organic anion transporters OATP1B1 and OATP1B3. J Lipid Res. 2006 Jun;47(6):1196-202.
8 Organic Anion-Transporting Polypeptide and Efflux Transporter-Mediated Hepatic Uptake and Biliary Excretion of Cilostazol and Its Metabolites in Rats and Humans. J Pharm Sci. 2017 Sep;106(9):2515-2523.
9 Contribution of OATP1B1 and OATP1B3 to the disposition of sorafenib and sorafenib-glucuronide. Clin Cancer Res. 2013 Mar 15;19(6):1458-66.
10 Effect of uptake transporters OAT3 and OATP1B1 and efflux transporter MRP2 on the pharmacokinetics of eluxadoline. J Clin Pharmacol. 2015 May;55(5):534-42.
11 The modified dipeptide, enalapril, an angiotensin-converting enzyme inhibitor, is transported by the rat liver organic anion transport protein. Hepatology. 1998 Nov;28(5):1341-6.
12 Role of transmembrane domain 10 for the function of organic anion transporting polypeptide 1B1. Protein Sci. 2009 Nov;18(11):2298-306.
13 Identification of drugs and drug metabolites as substrates of multidrug resistance protein 2 (MRP2) using triple-transfected MDCK-OATP1B1-UGT1A1-MRP2 cells. Br J Pharmacol. 2012 Mar;165(6):1836-1847.
14 A LC-MS/MS method to quantify the novel cholesterol lowering drug ezetimibe in human serum, urine and feces in healthy subjects genotyped for SLCO1B1. J Chromatogr B Analyt Technol Biomed Life Sci. 2006 Jan 2;830(1):143-50.
15 SLCO1B1 polymorphism and sex affect the pharmacokinetics of pravastatin but not fluvastatin. Clin Pharmacol Ther. 2006 Oct;80(4):356-66.
16 Liver Perfusion Modifies Gd-DTPA and Gd-BOPTA Hepatocyte Concentrations Through Transfer Clearances Across Sinusoidal Membranes. Eur J Drug Metab Pharmacokinet. 2017 Aug;42(4):657-667.
17 Transcellular movement of hydroxyurea is mediated by specific solute carrier transporters. Exp Hematol. 2011 Apr;39(4):446-56.
18 Identification of a novel gene family encoding human liver-specific organic anion transporter LST-1. J Biol Chem. 1999 Jun 11;274(24):17159-63.
19 A novel human hepatic organic anion transporting polypeptide (OATP2). Identification of a liver-specific human organic anion transporting polypeptide and identification of rat and human hydroxymethylglutaryl-CoA reductase inhibitor transporters. J Biol Chem. 1999 Dec 24;274(52):37161-8.
20 Role of organic anion-transporting polypeptides for cellular mesalazine (5-aminosalicylic acid) uptake. Drug Metab Dispos. 2011 Jun;39(6):1097-102.
21 Preclinical Mouse Models To Study Human OATP1B1- and OATP1B3-Mediated Drug-Drug Interactions in Vivo. Mol Pharm. 2015 Dec 7;12(12):4259-69.
22 Influence of SLCO1B1, 1B3, 2B1 and ABCC2 genetic polymorphisms on mycophenolic acid pharmacokinetics in Japanese renal transplant recipients. Eur J Clin Pharmacol. 2007 Dec;63(12):1161-9.
23 OATP1B1, OATP1B3, and mrp2 are involved in hepatobiliary transport of olmesartan, a novel angiotensin II blocker. Drug Metab Dispos. 2006 May;34(5):862-9.
24 Regulation of Organic Anion Transporting Polypeptides (OATP) 1B1- and OATP1B3-Mediated Transport: An Updated Review in the Context of OATP-Mediated Drug-Drug Interactions. Int J Mol Sci. 2018 Mar 14;19(3). pii: E855.
25 Interaction of human organic anion transporter polypeptides 1B1 and 1B3 with antineoplastic compounds. Eur J Med Chem. 2015 Mar 6;92:723-31.
26 Prediction of the in vivo OATP1B1-mediated drug-drug interaction potential of an investigational drug against a range of statins. Eur J Pharm Sci. 2012 Aug 30;47(1):244-55.
27 The effect of SLCO1B1*15 on the disposition of pravastatin and pitavastatin is substrate dependent: the contribution of transporting activity changes by SLCO1B1*15. Pharmacogenet Genomics. 2008 May;18(5):424-33.
28 Regorafenib is transported by the organic anion transporter 1B1 and the multidrug resistance protein 2. Biol Pharm Bull. 2015;38(4):582-6.
29 Disease-Associated Changes in Drug Transporters May Impact the Pharmacokinetics and/or Toxicity of Drugs: A White Paper From the International Transporter Consortium. Clin Pharmacol Ther. 2018 Nov;104(5):900-915.
30 Human organic anion transporting polypeptide-C (SLC21A6) is a major determinant of rifampin-mediated pregnane X receptor activation. J Pharmacol Exp Ther. 2003 Jan;304(1):223-8.
31 Involvement of multiple transporters in the hepatobiliary transport of rosuvastatin. Drug Metab Dispos. 2008 Oct;36(10):2014-23.
32 Drug-Drug Interactions with the NS3/4A Protease Inhibitor Simeprevir. Clin Pharmacokinet. 2016 Feb;55(2):197-208.
33 Impact of OATP transporters on pharmacokinetics. Br J Pharmacol. 2009 Oct;158(3):693-705.
34 Pharmacokinetic and pharmacodynamic interactions between the immunosuppressant sirolimus and the lipid-lowering drug ezetimibe in healthy volunteers. Clin Pharmacol Ther. 2010 Jun;87(6):663-7.
35 Coleman J., Cox A. and Cowley N. (2011). Side Effects of Drugs Annual. Elsevier.
36 Cellular entry of thyroid hormones by organic anion transporting polypeptides. Best Pract Res Clin Endocrinol Metab. 2007 Jun;21(2):209-21.
37 Analysis of amino acid residues in the predicted transmembrane pore influencing transport kinetics of the hepatic drug transporter organic anion transporting polypeptide 1B1 (OATP1B1). Biochim Biophys Acta. 2016 Nov;1858(11):2894-2902.
38 Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions. J Med Chem. 2012 May 24;55(10):4740-63.
39 Functional characterization of SLCO1B1 (OATP-C) variants, SLCO1B1*5, SLCO1B1*15 and SLCO1B1*15+C1007G, by using transient expression systems of HeLa and HEK293 cells. Pharmacogenet Genomics. 2005 Jul;15(7):513-22.
40 effect of OATP1B transporter inhibition on the pharmacokinetics of atorvastatin in healthy volunteers. Clin Pharmacol Ther. 2007 Feb;81(2):194-204.
41 Substrate-dependent drug-drug interactions between gemfibrozil, fluvastatin and other organic anion-transporting peptide (OATP) substrates on OATP1B1, OATP2B1, and OATP1B3. Drug Metab Dispos. 2007 Aug;35(8):1308-14.
42 Effect of pregnane X receptor ligands on transport mediated by human OATP1B1 and OATP1B3. Eur J Pharmacol. 2008 Apr 14;584(1):57-65.
43 Hepatic uptake of bilirubin and its conjugates by the human organic anion transporter SLC21A6. J Biol Chem. 2001 Mar 30;276(13):9626-30.
44 Contribution of OATP2 (OATP1B1) and OATP8 (OATP1B3) to the hepatic uptake of pitavastatin in humans. J Pharmacol Exp Ther. 2004 Oct;311(1):139-46.
45 Functional characterization of human organic anion transporting polypeptide B (OATP-B) in comparison with liver-specific OATP-C. Pharm Res. 2001 Sep;18(9):1262-9.
46 Multiple human isoforms of drug transporters contribute to the hepatic and renal transport of olmesartan, a selective antagonist of the angiotensin II AT1-receptor. Drug Metab Dispos. 2007 Dec;35(12):2166-76.
47 The development, characterization, and application of an OATP1B1 inhibition assay in drug discovery. Drug Metab Dispos. 2012 Aug;40(8):1641-8.
48 Transporter-mediated influx and efflux mechanisms of pitavastatin, a new inhibitor of HMG-CoA reductase. J Pharm Pharmacol. 2005 Oct;57(10):1305-11.
49 Interactions of rifamycin SV and rifampicin with organic anion uptake systems of human liver. Hepatology. 2002 Jul;36(1):164-72.
50 Drug and bile acid transporters in rosuvastatin hepatic uptake: function, expression, and pharmacogenetics. Gastroenterology. 2006 May;130(6):1793-806.
51 Rosuvastatin pharmacokinetics in heart transplant recipients administered an antirejection regimen including cyclosporine. Clin Pharmacol Ther. 2004 Aug;76(2):167-77.
52 Prediction of pharmacokinetic profile of valsartan in human based on in vitro uptake transport data. J Pharmacokinet Pharmacodyn. 2009 Dec;36(6):585-611.
53 Involvement of transporters in the hepatic uptake and biliary excretion of valsartan, a selective antagonist of the angiotensin II AT1-receptor, in humans. Drug Metab Dispos. 2006 Jul;34(7):1247-54.
54 Role of organic anion-transporting polypeptides, OATP-A, OATP-C and OATP-8, in the human placenta-maternal liver tandem excretory pathway for foetal bilirubin. Biochem J. 2003 May 1;371(Pt 3):897-905.
55 Organic anion-transporting polypeptide B (OATP-B) and its functional comparison with three other OATPs of human liver. Gastroenterology. 2001 Feb;120(2):525-33.
56 Identification, Ki determination and CoMFA analysis of nuclear receptor ligands as competitive inhibitors of OATP1B1-mediated estradiol-17beta-glucuronide transport. Pharmacol Res. 2009 Jul;60(1):50-6.
57 Effects of fibrates on human organic anion-transporting polypeptide 1B1-, multidrug resistance protein 2- and P-glycoprotein-mediated transport. Xenobiotica. 2005 Jul;35(7):737-53.

If you find any error in data or bug in web service, please kindly report it to Dr. Yin and Dr. Li.